_sreen.jpg)
Mistelikirjallisuus
Lisätietoja tutkimuksista
Forschungsinstitut Havelhöhe, Berlin (DE)
Institut für angewandte Erkenntnistheorie und medizinische Methodologie e. V. Freiburg i.Br. (DE)
Verein für Krebsforschung e.V., Forschungsinstitut HISCIA (CH)
Medizinische Sektion der Freien Hochschule für Geisteswissenschaft
Tutkimukset aakkosjärjestyksessä L-Z
(Tutkimukset aakkosjärjestyksessä A-K)
Lange-Lindberg A M, Velasco Garrido M and Busse R. Mistletoe treatments for minimising side effects of anticancer chemotherapy. GMS Health Technol Assess 2006;2:Doc18.
Leroi R, Hajto T. Die Iscadortherapie beim Ovarialkarzinom. Krebsgeschehen. 1982;14(2): 38–44.
Leroi R. Die Iscadorbehandlung bei inoperablen kolo-rektalen Tumoren. Krebsgeschehen. 1979; 11(6): 163–5.
Leroi R. Nachbehandlung des operierten Mammakarzinoms mit Viscum album. Helv Chir Acta. 1977 Jun; 44(3): 403–14.
Leroi R. Malignomtherapie mit neuen Iscador-Praparaten. Krebsgeschehen. 1975; 7(5):124–6.
Lipp HP. Mythos Mistel – Metaanalysen, neuere Studiendaten und aktuelle Marktübersicht. Krankenhauspharmazie 2017;12:543-555.
Loef, M., Paepke, D., & Walach, H. (2023). Quality of Life in Breast Cancer Patients Treated With Mistletoe Extracts: A Systematic Review and Meta-Analysis. Integrative Cancer Therapies, 22, 15347354231198074. https://doi.org/10.1177/15347354231198074
Loef, M., & Walach, H. (2022). Survival of Cancer Patients Treated with Non-Fermented Mistletoe Extract: A Systematic Review and Meta-Analysis. Integr Cancer Ther, 21, 15347354221133561. https://doi.org/10.1177/15347354221133561
Loef M and Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. BMC Complement Med Ther 2020; 20:227. doi.org/10.1186/s12906-020-03013-3.
Loewe-Mesch A, Kuehn J J, Borho K, Abel U, Bauer C, Gerhard I, Schneeweiss A, Sohn C, Strowitzki T and v Hagens C. [Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolerability]. Forsch Komplementmed, 2008;15:22-30. DOI: 10.1159/000112860.
Longhi, A, Cesari, M, Serra, M, Mariani, E. Long-term follow-up of a randomized study of oral etoposide versus Viscum album fermentatum pini as maintenance therapy in osteosarcoma patients in complete surgical remission after second relapse. Sarcoma. 2020;2020:8260730. doi:10.1155/2020/8260730
Google Scholar | Crossref | Medline
Longhi A, Reif M, Mariani E and Ferrari S. A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients. Evid Based Complement Alternat Med, 2014;2014:210198. DOI: 10.1155/2014/210198.
Longhi A, Mariani E and Kuehn J J. A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients. Eur J Integr Med, 2009;1:31-39.
Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, Fouladbakhsh JM, Gil B, Hershman DL, Mansfield S, Mussallem DM, Mustian KM, Price E, Rafte S and Lorenzo Cohen. Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. J Clin Oncol.2018:36:2647-2655.
Ma L, Phalke S, Stevigny C, Souard F, Vermijlen D: Mistletoe-extract drugs stimulate anti-cancer Vγ9Vδ2 T cells. Cells 2020, 9 (6), 1560. 15 pp. DOI: 10.3390/cells9061560.
Mabed M, El-Helw L and Shamaa S. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. British Journal of Cancer, 2004;90:65-69. DOI: 10.1038/sj.bjc.6601463.
Maier G, Fiebig HH. Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs. 2002 Apr;13(4):373-9.
Maldacker J. Preclinical investigations with mistletoe (Viscum album L.) extract Iscador. Arzneimittelforschung, 2006;56:497-507. DOI: 10.1055/s-0031-1296817.
Mansky PJ, Wallerstedt DB, Sannes TS, Stagl J, Johnson LL, Blackman MR, Grem JL, Swain SM and Monahan BP. NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evid Based Complement Alternat Med. 2013;2013:964592. doi:10.1155/2013/964592. Epub 2013 Oct 27.
Matthes H, Thronicke A, Hofheinz R-D, Baars E, Martin D, Huber R, Breitkreuz T, Bar-Sela G, Galun D and Schad F. Statement to an Insufficient Systematic Review on Viscum album L. Therapy. Evidence-Based Complementary and Alternative Medicine, Volume 2020, Article ID 7091039, 9 pages. Open Access.
Matthes H, Hofheinz RD, Bar-Sela D, Galun D, Martin D, Huber R, Langhorts J, Matthiessen PF and Schad F. Letter to the editors of the Journal of Cancer Research and Clinical Oncology. J Cancer Res Clin Oncol 2019;145: 2405–2407
Matthes H. Die Misteltherapie in der Onkologie – ein Update. Praxismagazin 2017;9:6-14.
Matthes H, Friedel W E, Bock P R and Zanker K S. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med, 2010;10:430-439. DOI: 10.2174/156652410791317057.
Mehl A, Reif M, Zerm R, Pranga D, Friemel D, Berger B, Brinkhaus B, Gutenbrunner C, Büssing A and Kröz M: Impact of a Multimodal and Combination Therapy on Self-Regulation and Internal Coherence in German Breast Cancer Survivors With Chronic Cancer-Related Fatigue: A Mixed-Method Comprehensive Cohort Design Study. Integr Cancer Ther 2020; 19:1534735420935618. doi: 10.1177/1534735420935618.
Menke K, Schwermer M, Eisenbraun J, Schramm A, Zuzak TJ: Anticancer effects of Viscum album Fraxini extract on medulloblastoma cells in vitro. Complementary Medicine Research 2020. 8 pp. DOI: 10.1159/000507318.
Melzer J, Iten F, Hostanska K and Saller R. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forsch Komplementmed, 2009;16:217-226. DOI: 10.1159/000226249.
Matthiessen PF, Tröger W. Die Misteltherapie des Krebses. In Kombinierte Tumortherapie. (Ed. Wrba H) pp. 271-290, Hippokrates Verlag, Stuttgart 1995.
Micke O, Buntzel J, Kisters K, Schäfer U, Micke P and Mücke R. Complementary and alternative medicine in lung cancer patients: a neglected phenomenon? Frontiers of Radiation Therapy and Oncology 2009;42:198–205.
Mueller EA and Anderer FA. A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother 1990;32:221-227.
Mulsow K, Enzlein T, Delebinski C, Jaeger S, Seifert G and Melzig MF. Impact of Mistletoe Triterpene Acids on the Uptake of Mistletoe Lectin by Cultured Tumor Cells. PLOS One 2016;11: e0153825.
Nazaruk J and Orlikowski P. Phytochemical profile and therapeutic potential of Viscum album L. Nat Prod Res 2016;30:373-385.
Oei SL and Schad F. (2023) Are Aspects of Integrative Concepts Helpful to Improve Pancreatic Cancer Therapy? Cancers. 2023; 15(4):1116. https://doi.org/10.3390/cancers15041116.
Oei SL, Thronicke A, Matthes H, Schad F. Evaluation of the effects of integrative non-pharmacological interventions on the internal coherence and resilience of breast cancer patients. Support Care Cancer. 2021;29(3):1413-21. DOI: 10.1007/s00520-020-05617-4.
Oei SL, Thronicke A, Kröz, M, von Trott P, Schad F, Matthes, H. Impact of Oncological Therapy and Viscum album L Treatment on Cancer-Related Fatigue and Internal Coherence in Nonmetastasized Breast Cancer Patients. Integr Cancer Ther. 2020;19:1534735420917211. doi: 10.1177/1534735420917211
Oei SL, Thronicke A, Matthes H & Schad F. Evaluation of the effects of integrative non-pharmacological interventions on the internal coherence and resilience of breast cancer patients [published online ahead of print, 2020 Jul 15]. Support Care Cancer. 2020;10.1007/s00520-020-05617-4. doi: 10.1007/s00520-020-05617-4
Oei S L, Thronicke A and Schad F. Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies. Evid Based Complement Alternat Med, 2019;2019:5893017. DOI: 10.1155/2019/5893017.
Oei SL, Thronicke A, Kröz M, Herbstreit C and Schad F. Supportive effect of Viscum album L. extracts on the sense of coherence in non-metastasized breast cancer patients. European Journal of Integrative Medicine. 2019;27:97-104.
Oei SL, Thronicke A, Kröz M, Matthes H and Schad F. Use and Safety of Viscum album L Applications in Cancer Patients With Preexisting Autoimmune Diseases: Findings From the Network Oncology Study. Integr Cancer Ther. 2019;18:1534735419832367.
Oei SL, Thronicke A, Kröz M, Herbstreit C and Schad F. The Internal Coherence of Breast Cancer Patients Is Associated with the Decision-Making for Chemotherapy and Viscum album L. Treatment. Evid Based Complement Alternat Med 2018;2018:1065271.
Oh SJ: Reducing malignant ascites and long-term survival in a patient with recurrent gastric cancer treated with a combination of Docetaxel and mistletoe extract. Case Reports in Oncology 2020, 13 (2), 528-533. DOI: 10.1159/000507282.
Orange M, Poidimani N, Crosignani A, Werthmann PG, Bertotto C. Complete, Durable Remission of Advanced Hepatocellular Carcinoma Under Treatment with Viscum Album Extracts – A Case Report. SSRN Journal. Published online 2021. DOI: 10.2139/ssrn.3775671
Orange M, Lace A, Fonseca M P, von Laue B H, Geider S and Kienle GS. Durable Regression of Primary Cutaneous B-Cell Lymphoma Following Fever-inducing Mistletoe Treatment: Two Case Reports. Glob Adv Health Med, 2012;1:18-25. DOI: 10.7453/gahmj.2012.1.1.006.
Orange M, Fonseca MP, Lace A, von Laue HB and Geider S. Durable tumour responses following primary high does induction with mistletoe extracts. Two case reports. European Journal of Integrative Medicine, 2010;2:63-69. DOI: 10.1016/j.eujim.2010.04.001.
Ostermann T, Appelbaum S, Poier D, Boehm K, Raak C, Büssing A. A systematic review and meta-analysis on the survival of cancer patients treated with a fermented Viscum album L. extract (Iscador): an update of findings. Complementary Medicine Research 2020;27(4)260-271.
Ostermann T and Büssing A. Retrolective studies on the survival of cancer patients treated with mistletoe extracts: a meta-analysis. Explore (NY) 2012;8:277-281.
Ostermann T, Raak C and Bussing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer, 2009;9:451. DOI: 10.1186/1471-2407-9-451.
Pae HO, Oh GS, Seo WG, Shin MK, Hong SG, Lee HS and Chung HT. Mistletoe lectin synergizes with paclitaxel in human SK-hep1 hepatocarcinoma cells. Immunopharmacol Immunotoxicol 2001;23: 531-540.
Paepke D. Die Misteltherapie in der Onkologie. Im Focus Onkologie 2018;21:64–68.
Pal A, Debreczeni JE, Sevvana M, Gruene T, Kahle B, Zeeck A and Sheldrick GM. Structures of viscotoxins A1 and B2 from European mistletoe solved using native data alone. Acta Crystallogr D Biol Crystallogr 2008;64:985-992.
Pal A. Structure determination of Viscotoxin A1, Tendamistat and Tri Peptidyl Peptidase-I. Dissertation. Göttingen 2008, University Göttingen.
Paller, C. J., Wang, L., Fu, W., Kumar, R., Durham, J. N., Azad, N. S., Laheru, D. A., Browner, I., Kachhap, S. K., Boyapati, K., Odeny, T., Armstrong, D. K., Meyer, C. F., Gaillard, S., Brahmer, J. R., Page, I., Wang, H., & Diaz, L. A., Jr. (2023). Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer. Cancer Res Commun, 3(2), 338-346. https://doi.org/10.1158/2767-9764.Crc-23-0002
Pelzer F, Loef M, Martin DD, Baumgartner S. Cancer related fatigue in patients treated with mistletoe extracts: a systematic review and meta analysis . Supportive Care in Cancer 2022.
Open access DOI: https://doi.org/10.1007/s00520-022-06921-x.
Pelzer F, Tröger W and Nat D R. Complementary Treatment with Mistletoe Extracts During Chemotherapy: Safety, Neutropenia, Fever, and Quality of Life Assessed in a Randomized Study. J Altern Complement Med, 2018;24:954-961. DOI: 10.1089/acm.2018.0159.
Penaloza E, Holandino C, Scherr C, et al. Comprehensive metabolome analysis of fermented aqueous extracts of Viscum album L. by liquid chromatography-high resolution tandem mass spectrometry. Molecules 2020;25(17):4006. DOI: https:// doi.org/10.3390/molecules 25174006.
Pfüller U (2000). Chemical constituents of European mistletoe (Viscum album L.). In: Büssing A: Mistletoe - The Genus Viscum. pp 1-122. Amsterdam, Harwood Academic Publishers Amsterdam 2000.
Piao B K, Wang Y X, Xie G R, Mannsmann U, Matthes H, Beuth J and Lin H S. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Research 2004;24:303-310.
Pichler W J and Angeli R. [An allergy to mistletoe extract]. Dtsch Med Wochenschr, 1991;116:1333-1334.
Pietrzak W, Nowak R, Gawlik-Dziki U, Lemieszek MK, Rzeski W. LC-ESI-MS/MS identification of biologically active phenolic compounds in mistletoe berry extracts from different host trees. Molecules 2017;22:264. DOI: 10.3390/molecules22040624.
Podlech OP, Harter PN, Mittelbronn M, Pöschel S and Naumann U. Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med. 2012;2012:501796. doi: 10.1155/2012/501796. Epub 2012 Oct 22.
Poier D, Bussing A, Rodrigues Recchia D, Beerenbrock Y, Reif M, Nikolaou A, Zerm R, Gutenbrunner C and Kröz M. Influence of a Multimodal and Multimodal-Aerobic Therapy Concept on Health-Related Quality of Life in Breast Cancer Survivors. Integr Cancer Ther. 2019;18:1534735418820447.
Ramm H, Schaller G, Urech K, Baumgartner S. Iscador – Pharmazeutische Grundlagen und spirituelles Verständnis für die Verarbeitung der Mistel zum Krebspräparat. Der Merkurstab. Zeitschrift für Anthroposophische Medizin
2021;74(3):219-226. DOI: https://doi.org/10.14271/DMS-21357-DE
Reynel M, Villegas Y, Werthmann PG, Kiene and Kienle GS. Long-term survival of a patient with an inoperable thymic neuroendocrine tumor stage IIIa under sole treatment with Viscum album extract
A CARE compliant clinical case report. Medicine (Baltimore). 2020 Jan; 99(5): e18990. Published online 2020 Jan 31. doi: 10.1097/MD.0000000000018990
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004773/
Reynel M, Villegas Y, Kiene H, Werthmann PG, Kienle GS . Bilateral Asynchronous Renal Cell Carcinoma With Lung Metastases: A Case Report of a Patient Treated Solely With High-dose Intravenous and Subcutaneous Viscum album Extract for a Second Renal Lesion. Anticancer Res. 2019 Oct;39(10):5597-5604. doi: 10.21873/anticanres.13754.
Reynel M, Villegas Y, Kiene H, Werthmann P and Kienle GS. Intralesional and subcutaneous application of Viscum album L.(European mistletoe) extract in cervical carcinoma in situ: A CARE compliant case report. Medicine: November 2018 - Volume 97 - Issue 48 - p e13420 doi: 10.1097/MD.0000000000013420.
Ribereau-Gayon G, Jung ML, Baudino S, Salle G and Beck JP. Effects of mistletoe (Viscum album L.) extracts on cultured tumor cells. Experientia 1986;42:594-599.
Rieger S. Immunologische Effekte verschiedener Mistelextrakte in Wechselwirkung mit humanen Tumorzellüberständen – ein Modell mit Dendritischen Zellen. Dissertation, Universität Freiburg, 2015.
Rose A, El-Leithy T, vom Dorp F, et al. Mistletoe plant extract in patients with non-muscle invasive bladder cancer: results of a phase Ib/IIa single group dose escalation study. The Journal of Urology 2015;194:939–943. DOI: https://doi.org/ 10.1016/ j.juro.2015.04.073.
Saha C, Das M, Stephen-Victor E, Friboulet A, Bayry J and Kaveri S V. Differential Effects of Viscum album Preparations on the Maturation and Activation of Human Dendritic Cells and CD4(+) T Cell Responses. Molecules, 2016;21. DOI: 10.3390/molecules21070912.
Salzer G, Danmayr E, Wutzlhofer F, Frey S. Adjuvante Iscador-Behandlung operierter nicht kleinzelliger Bronchuskarzinome. Ergebnisse einer randomisierten Studie. Dtsch Z Onkol. 1991; 23(4): 94–8.
Salzer G, Havelec L. Adjuvante Iscador-Behandlung nach operiertem Magenkarzinom. Ergebnisse einer randomisierten Studie.
Krebsgeschehen. 1983; 15(4): 106–10.
Salzer G, Havelec L. Rezidivprophylaxe bei operierten Bronchuskarzinompatienten mit dem Mistelpraparat Iscador: Ergebnisse
eines klinischen Versuchs aus den Jahren 1969-1971. Onkologie. 1978 Dec; 1(6): 264–7.
Sander F. Wirkung des Mistellektin-l auf das Wachstums- und Metastasierungsverhalten der humanen Melanomzelllinie MV3 in vivo in einem Xenograftmodell mit scid- und pfp/rag2-Mäusen. Dissertation, University Hamburg, 2008.
Schad F, Steinmann D, Oei SL, Thronicke A, Grah C. Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study. Radiation Oncology 2023;18:47. DOI: https://doi.org/10.1186/ s13014-023-02234-3.
Schad F, Thronicke A. Safety of Combined Targeted and Helixor® Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study. International Journal of Environmental Research and Public Health 2023;20:2565. DOI: https://doi.org/10.3390/ijerph 20032565.
Schad F, Thronicke A, von Trott P, Oei SL: Analysis of changes in cancer-related fatigue of breast cancer patients receiving an integrative medicine program. Integrative Cancer Therapies 2020, 19. 12 pp. DOI: 10.1177/1534735420963780.
Schad F, Thronicke A, Steele M L, Merkle A, Matthes B, Grah C and Matthes H. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One, 2018;13:e0203058. DOI: 10.1371/journal.pone.0203058.
Schad F, Thronicke A, Merkle A, Steele M, Kröz M, Herbstreit C and Matthes H. Implementation of an integrative oncological concept in daily care of a German certified Breast Cancer Centre. Complement Med Res 2018;25:85-91.
Schad F, Axtner J, Kroz M, Matthes H and Steele M L. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations. Integr Cancer Ther, 2018;17:41-51. DOI: 10.1177/1534735416681641.
Schad F, Thronicke A, Merkle A, Matthes H and Steele ML. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients. Phytomedicine 2017;36:54-58.
Schad, F, Atxner, J, Buchwald, D, et al. Intratumoral mistletoe (Viscum album L.) therapy in patients with unresectable pancreas carcinoma: a retrospective analysis. Integr Cancer Ther. 2014;13(4):332-340. doi:10.1177/1534735413513637
Google Scholar | SAGE Journals | ISI
Schad F, Axtner J, Happe A, Breitkreuz T, Paxino C, Gutsch J, Matthes B, Debus M, Kröz M, Spahn G, Riess H, von Laue HB and Matthes H. Network Oncology (NO)--a clinical cancer register for health services research and the evaluation of integrative therapeutic interventions in anthroposophic medicine. Forsch Komplementmed 2013;20:353-360.
Scheer R., Alban S., Becker H., Beer A.-M., Blaschek W., Kreis. W., Matthes H., Schilcher H.† , Spahn G., Stange R. (Hrsg.): "Die Mistel in der Tumortherapie - 4, aktueller Stand der Forschung und klinische Anwendung", 469 Seiten, KVC-Verlag Essen 2016, ISBN 978-3-945150-68-9. Sisällysluettelo
Scheer R ja Leneweit G. Das Mistelpräparat abnobaVISCUM. Der Merkurstab, Zeitschrift für Anthroposophische Medizin2021;74(3):208-214. DOI: https://doi.org/10.14271/DMS-21355-DE
Scheer R., Alban S., Becker H., Blaschek W., Kemper F.H., Kreis. W., Matthes H., Schilcher H., Stange R. (Hrsg.): "Die Mistel in der Tumortherapie - 3, aktueller Stand der Forschung und klinische Anwendung", 502 Seiten, KVC-Verlag Essen 2013, ISBN 978-3-86864-032-8.
Scheer R., Alban S., Becker H., Holzgrabe U., Kemper F.H., Kreis W., Matthes H., Schilcher H. (Hrsg.): "Die Mistel in der Tumortherapie 2, Aktueller Stand der Forschung und klinische Anwendung", 642 Seiten, KVC-Verlag Essen 2009, ISBN 978-3-933351-82-1.
Scheer R., Bauer R., Becker H., Fintelmann V., Kemper F.H., Schilcher H. (Hrsg.): "Fortschritte in der Misteltherapie, Aktueller Stand der Forschung und klinische Anwendung", 662 Seiten, KVC Verlag Essen 2005, ISBN 3-933351-49-9.
Scheffler A, Richter M, Beffert M, Errenst M, Scheer R. Differenzierung der Mistelinhaltsstoffe nach Zeit und Ort. In: Scheer R, Becker H, Berg PA (Hg). Grundlagen der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung. Stuttgart: Hippokrates Verlag, Stuttgart; 1996, ISBN 3-7773-1239-8: 1996: 49–76
Schibel S, Steinert M, Matthes H, Grah C. ACCEPT®: A Complementary Anthroposophical Program for the Palliative Treatment of Lung Cancer – Rationale and a Randomized Feasibility Study. Complement Med Res. 2021;28(4). DOI: 10.1159/000516820.
Schink M and Dehus O. Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities. BMC Complement Altern Med, 2017;17:521. DOI: 10.1186/s12906-017-2028-1.
Schink M, Tröger W, Goyert A, Scheuerecker H, Meyer J, Fischer I and Glaser F (2009). Einfluss perioperativer Mistelextrakt-Infusionen auf eine operations- und narkosebedingte Immunsuppression bei Patienten mit kolorektalem Karzinom. S. 441-454. Die Mistel in der Tumortherapie 2. R. Scheer, S. Alban, H. Becker et al. Essen, KVC Verlag. 2009: S. 441-454.
Schink M, Tröger W, Dabidian A, Goyert A, Scheuerecker H, Meyer J, Fischer I U and Glaser F. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. a randomized phase III trial. Forsch Komplementmed, 2007;14:9-17. DOI: 10.1159/000098135.
Schink M, Tröger W, Goyert A, Scheuerecker H, Selbmann H K and Glaser F. [Correlation of NK cell activity against autologous tumour cells and K562 cells with the clinical outcome during therapy with mistletoe extracts]. Forsch Komplementmed, 2006;13:147-155. DOI: 10.1159/000092624.
Schink M and M Borowsky (2001). Zytotoxische Effekte von Mistellektinen und einem Mistelpräparat auf menschliche natürliche Killerzellen in vitro. 163-176. In: Scheer R., Bauer R., Becker H., Berg P. A., Fintelmann V. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik: 163-176. KVC Verlag Essen 2001, ISBN 3-933351-22-7
Schläpfer, D, Urech, K. Three cases of remission of actinic keratosis, basal-cell carcinoma and squamous-cell carcinoma respectively by topical therapy with “Viscum album, Resina 10%, Unguentum.” Phytomedicine. 2019;61:8. doi:10.1016/j.phymed.2019.09.093
Google Scholar | Crossref
Schläppi M, Ewald C, Kuehn JJ, Weinert T and Huber R. Fever Therapy With Intravenously Applied Mistletoe Extracts for Cancer Patients: A Retrospective Study. Integrative Cancer Therapies 2016;16(4):479-484.
Schlodder D. Hintergründe des Helixor-Herstellungsprozesses. Der Merkurstab. Zeitschrift für Anthroposophische Medizin 2021;74(3):215-218. DOI: https://doi.org/10.14271/DMS-21356-DE
Schötterl S, Huber SM, Lentzen H, Mittelbronn M, Naumann U.Adjuvant therapy using mistletoe containing drugs boosts the T-cell-mediated killing of glioma cells and prolongs the survival of glioma bearing mice. Evidence-Based Complementary and Alternative Medicine 2018. Article ID 3928572. 12 pp. DOI: 10.1155/2018/3928572.
Schuppli R. Die adjuvante Behandlung des malignen Melanoms mit Iscador c. Hg. In: Jungi WF, Senn HJ, editors. Krebs und Alternativmedizin II. Berlin, Heidelberg: Springer Verlag; 1990. p. 84–87.
Seifert, G, Jesse, P, Laengler, A, et al. Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett. 2008;264(2):218-228. doi:10.1016/j.canlet.2008.01.036
Google Scholar | Crossref | Medline
Siegle I, Fritz P, McClellan M, Gutzeit S and Murdter TE. Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. Anticancer Res 2001;21:2687-2691.
Stammer RM, Kleinsimon S, Rolff J, Jäger S, Eggert A, Seifert G, Delebinski CI (2017) Synergistic antitumour properties of viscumTT in alveolar rhabdomyosarcoma. Journal of Immunology Research 2017. 13 pp. Article ID 4874280. DOI: 10.1155/2017/4874280.
Stauder H, Kreuser ED. Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie. 2002;25:374-380.
Steele ML, Axtner J, Happe A, Kröz M, Matthes H and Schad F. Use and Safety of Intratumoral Application of European Mistletoe (Viscum album L) Preparations in Oncology. Integrative Cancer Therapies, 2015;14:140-148. DOI: 10.1177/1534735414563977.
Steele ML, Axtner J, Happe A, Kroz M, Matthes H and Schad F. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients. Evid Based Complement Alternat Med, 2014;2014:724258. DOI: 10.1155/2014/724258.
Steele ML, Axtner J, Happe A, Kroz M, Matthes H and Schad F. Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study. Evid Based Complement Alternat Med, 2014;2014:236310. DOI:10.1155/2014/236310.
Stefanucci A, Zengin G, Llorent-Martinez EJ, Dimmito MP, Della Valle A, Pieretti S, Ak G, Sinan KI, Mollica A: Viscum album L. homogenizer-assisted and ultrasound-assisted extracts as potential sources of bioactive compounds. Journal of Food Chemistry 2020, article ID e13377. 12 pp. DOI: 10.1111/jfbc.13377.
Stein GM, U Edlund, G Schaller, U Pflüller, A Büssing and M Schietzel (2001). Polysaccharide und Viscotoxine – Immunologische Wirkungen und Interaktionen. In: Scheer R., Bauer R., Becker H., Berg P. A., Fintelmann V. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik:.145-161. KVC Verlag Essen 2001, ISBN 3-933351-22-7.
Stein G M and Berg P A. Adverse effects during therapy with mistletoe extracts. In: Büssing A, editor. Mistletoe The Genus Viscum Amsterdam, Hardwood Academic Publishers; 2000. p. 195-208.
Stein GM and Berg PA. Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Anticancer Drugs 1997;8 Suppl 1:39-42.
Stein GM, Stettin A, Schultze J and Berg PA. Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts. Anticancer Drugs 1997;8 Suppl 1:57-59.
Steinborn C, Klemd A M, Sanchez-Campillo A S, Rieger S, Scheffen M, Sauer B, Garcia-Kaufer M, Urech K, Follo M, Ucker A, Kienle G S, Huber R and Grundemann C. Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model. PLoS One, 2017;12:e0181553. DOI: 10.1371/journal.pone.0181553.
Stettin A, Schultze JL, Stechemesser E and Berg PA. Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro. Klin Wochenschr 1990;68:896-900.
Szurpnicka A, Kowalczuk A, Szterk A: Biological activity of mistletoe: in vitro and in vivo studies and mechanisms of action. Archives of Pharmacol Research 2020, 43 (6), 593-629. DOI: 10.1007/s12272-020-01247-w
Tabiasco J, Pont F, Fournie J J and Vercellone A. Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity. Eur J Biochem, 2002;269:2591-2600. DOI: 10.1046/j.1432-1033.2002.02932.x.
Templeton AJ, Thurlimann B, Baumann M, Mark M, Stoll S, Schwizer M, Dietrich D and Thomas Ruhstaller T. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors. BMC Cancer 2013;13:153.
Thronicke, A., Schad, F., Debus, M., Grabowski, J., & Soldner, G. (2022). Viscum album L. Therapy in Oncology: An Update on Current Evidence. Complement Med Res, 29(4), 362-368. https://doi.org/10.1159/000524184 (Viscum album L. Therapie in der Onkologie: Ein Update zur bestehenden Evidenz.)
Thronicke A, Matthes B, von Trott P, Schad F & Grah C. Overall Survival of Non-metastasized NSCLC Patients Treated With Add-On Viscum album L. Integr Cancer Ther. 2020; doi: 10.1177/1534735420940384
Thronicke A, Reinhold T, von Trott P, Grah C, Matthes B, Matthes H & Schad F. Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients. Plos ONE. 2020;15(7):e0236426. Published 2020 Jul 27. doi: 10.1371/journal.pone.0236426
Thronicke A, von Trott P, Kröz M, Grah C, Matthes B & Schad F. Health-Related Quality of Life in Patients with Lung Cancer Applying Integrative Oncology Concepts in a Certified Cancer Centre. Evid Based Complement Alternat Med. 2020;2020:5917382. Published 2020 May 10. doi: 10.1155/2020/5917382
Thronicke A, Reinhold T, von Trott P, Matthes H & Schad F. Cost-Effectiveness of Real-World Administration of Concomitant Viscum album L. Therapy for the Treatment of Stage IV Pancreatic Cancer. Evid Based Complement Alternat Med. 2020;2020:3543568. Published 2020 Mar 12. doi: 10.1155/2020/3543568
Thronicke A, Oei S L, Merkle A, H M and Schad F. Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients. Medicines (Basel), 2018;5:100. DOI: 10.3390/medicines5030100.
Thronicke A, Oei SL, Merkle A, Herbstreit C, Lemmens HP, Grah C, Kröz M, Matthes H and Schad F. Integrative cancer care in a certified Cancer Centre of a German Anthroposophic hospital. Complement Ther Med 2018;40:151-157.
Thronicke A, Steele M L, Grah C, Matthes B and Schad F. Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complement Altern Med, 2017;17:534. DOI: 10.1186/s12906-017-2045-0.
Tröger W, Zdrale Z and Stankovic N. Fünf-Jahres-Nachbeobachtung von Patientinnen mit Brustkrebs nach einer randomisierten Studie mit Viscum album (L.) Extrakt. Deutsche Zeitschrift für Onkologie, 2016;48:105-110. DOI: 10.1055/s-0042-113505.
Tröger W, Zdrale Z, Tisma N and Matijasevic M. Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial. Evidence-Based Complementary and Alternative Medicine, 2014;2014:01. Sep. DOI: 10.1155/2014/430518.
Tröger W, Galun D, Reif M, Schumann A, Stankovic N and Milicevic M. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Dtsch Arztebl Int, 2014;111:493-502, 433 p following 502. DOI: 10.3238/arztebl.2014.0493.
Tröger W, Galun D, Reif M, Schumann A, Stankovic N and Milicevic M. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer. A randomised clinical trial on overall survival. European Journal of Cancer, 2013;49:3788-3797. DOI: 10.1016/j.ejca.2013.06.043.
Tröger W, Zdrale Z, Stankovic N and Matijasevic M. Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with viscum album (L.) extract to chemotherapy alone. Breast Cancer (Auckl), 2012;6:173-180. DOI: 10.4137/BCBCR.S10558.
Tröger W, Jezdic S, Zdrale Z, Tisma N, Hamre H J and Matijasevic M. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer, 2009;3:35-45.
Tsekouras V, Mavrikou S, Vlachakis D, Makridakis M, Stroggilos R, Zoidakis J, Termentzi A, Moschopoulou G, Kintzios S: Proteome analysis of leaf, stem and callus in Viscum album and identification of lectins and viscotoxins with bioactive properties. Plant Cell, Tissue and Organ Culture 2020, 141 (1), 167-178. DOI: 10.1007/s11240-020-01777-7.
Twardziok, M, Meierhofer, D, Börno, S, et al. Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in ewing sarcoma cells reveals cellular stress responses. BMC Complement Altern Med. 2017;17(1):237. doi:10.1186/s12906-017-1715-2
Google Scholar | Crossref | Medline
Twardziok, M, Kleinsimon, S, Rolff, J, et al. Multiple active compounds from Viscum album L. synergistically converge to promote apoptosis in ewing sarcoma. PLoS One. 2016;11(9):e0159749. doi:10.1371/journal.pone.0159749
Google Scholar | Crossref | Medline
Urech K and Baumgartner S. Chemical constituents of Viscum album L. for the pharmaceutical preparation of mistletoe. In: Kurt S. Zänker, and Srini V. Kaveri, editors. (eds.), (2015) From mythology to evidence-based medicine. Translational Research in Biomedicine. Volume 4, pp 11-23. S. Karger AG, Basel, Switzerland ISBN: 978-3-318-05444-6.
Urech K, C Jäggy and G Schaller (2009). Räumliche und zeitliche Dynamik der Viscotoxin- und Mistellektingehalte in der Mistel (Viscum album L.). In: Scheer R, Alban S, Becker H, Holzgrabe U, Kemper FH, Kreis W, Matthes H und Schilcher H (Hrsg.), Die Mistel in der Tumortherapie 2, S. 67-77. KVC Verlag, Essen 2009. ISBN 978-3-933351-82.
Urech K, Büssing A, Thalmann G, Schäfermeyer H and Heusser P. Antiproliferative effects of mistletoe (Viscum album L) extract in urinary bladder carcinoma cell lines. Anti-Cancer Research 2006;26:3049-3056.
Urech K, Schaller G and Jaggy C. Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung, 2006;56:428-434. DOI: 10.1055/s-0031-1296808.
Urech K, Scher JM, Hostanska K and Becker H. Apoptosis inducing activity of viscin, a lipophilic extract from Viscum album L. J Pharm Pharmacol 2005;57:101-109.
Urech K. Accumulation of arginine in Viscum album L.: Seasonal variations and host dependency. Journal of Plant Physiology 1997;151(1):1–5. DOI: https:// doi.org/10.1016/S0176-1617(97) 80029-6.
van Huyen JPD, Delignat S, Bayry J, Kazatchkine MD, Bruneva IP, Nicoletti A and Kaveri SV. Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Lett 2006;243:32-37.
von Hagens C, A Loewe-Mesch, JJ Kuehn, U Abel and I Gerhard (2005). Prospektive kontrollierte nicht randomisierte Machbarkeits-Studie zu einer postoperativen simultanen Mistel-/Chemotherapie bei Patientinnen mit Mammakarzinom - Ergebnisse zu Rekrutierbarkeit, Immunparametern, Lebensqualität und Verträglichkeit. In: Scheer R, Bauer H. Becker R et al. Fortschritte in der Misteltherapie. Stand der Forschung und klinischen Anwendung. Essen, KVC Verlag, 2005. S. 567-578.
von Schoen-Angerer T, Wilkens J, Kienle G S, Kiene H and Vagedes J. High-Dose Viscum album Extract Treatment in the Prevention of Recurrent Bladder Cancer: A Retrospective Case Series. Perm J, 2015;19:76-83. DOI: 10.7812/TPP/15-018.
von Schoen-Angerer, T, Goyert, A, Vagedes, J, Kiene, H, Merckens, H, Kienle, GS. Disappearance of an advanced adenomatous colon polyp after intratumoural injection with Viscum album (European mistletoe) extract: a case report. J Gastrointestin Liver Dis. 2014;23(4):449-452. doi:10.15403/jgld.2014.1121.234.acpy
Google Scholar | Crossref | Medline
Waschakidze, T. Intraläsionale Misteltherapie bei einer Patientin mit Liposarkom – eine Fallvignette aus Georgien. Der Merkurstab. 2016;69(3):205-207. doi:10.14271/DMS-20638-DE
Google Scholar | Crossref
Weissenstein U, Kunz M, Oufir M, Wang J T, Hamburger M, Urech K, Regueiro U and Baumgartner S. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. BMC Complement Altern Med, 2019;19:23. DOI: 10.1186/s12906-019-2439-2.
Weissenstein U, Kunz M, Urech K, Regueiro U and Baumgartner S. Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro. BMC Complement Altern Med 2016;16:271.
Weissenstein U, Kunz M, Urech K and Baumgartner S. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complementary and Alternative Medicine, 2014;14:01. Sep. DOI: 10.1186/1472-6882-14-6.
Werthmann PG, Kindermann L, Kienle GS. Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with Viscum album Extracts. Complementary Medicine Research. March 2019:1-4. DOI:10.1159/000496866 .
Werthmann PG, Kempenich R, Kienle GS. Long-term tumor-free survival in a patient with stage IV epithelial ovarian cancer undergoing high-dose chemotherapy and viscum album extract treatment: A case report. Perm J 2019;23:18-025. DOI: https://doi.org/10.7812/TPP/18-025.
Werthmann PG, Kempenich R, Lang-Avérous G, Kienle, GS. Long-term Survival of a Patient With Advanced Pancreatic Cancer Under Adjunct Treatment With Viscum album Extracts – A Case Report. World J Gastroenterol. March 2019. DOI: 10.3748/wjg.v25.i12.0000.
Werthmann PG, Kindermann L and Kienle GS. A 21-year course of Merkel cell carcinoma with adjuvant Viscum album extract treatment: A case report. Complement Ther Med 2018;38:58-60.
Werthmann PG, Inter P, Welsch T, Sturm AK, Grutzmann R, Debus M, Sterner MG and Kienle GS. Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/Mitomycin, high-dose, fever inducing Viscum album extracts and subsequent R0 resection: A case report. Medicine (Baltimore) 2018;97:e13243.
Werthmann P G, Huber R and Kienle G S. Durable clinical remission of a skull metastasis under intralesional Viscum album extract therapy: Case report. Head Neck, 2018;40:E77-E81. DOI: 10.1002/hed.25320.
Werthmann PG, Saltzwedel G, Kienle GS. Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report. J Thorac Dis 2017;9(12):E1064–E1070. doi:10.21037/jtd.2017.11.56.
Werthmann P G, Hintze A and Kienle G S. Complete remission and long-term survival of a patient with melanoma metastases treated with high-dose fever-inducing Viscum album extract: A case report. Medicine (Baltimore), 2017;96:e8731. DOI: 10.1097/MD.0000000000008731.
Werthmann P G, Helling D, Heusser P and Kienle G S. Tumour response following high-dose intratumoural application of Viscum album on a patient with adenoid cystic carcinoma. BMJ Case Rep, 2014;2014. DOI: 10.1136/bcr-2013-203180.
Werthmann P G, Strater G, Friesland H and Kienle G S. Durable response of cutaneous squamous cell carcinoma following high-dose perilesional injections of Viscum album extracts--a case report. Phytomedicine, 2013;20:324-327. DOI: 10.1016/j.phymed.2012.11.001.
Witt CM and Cardoso MJ. Complementary and integrative medicine for breast cancer patients - Evidence based practical recommendations. The Breast 2016;28:37-44.
Wode, K., Hök Nordberg, J., Kienle, G.S., Elander N.O, Bernhardson B.-M., Sunde B., Sharp L., Henriksson R. et Fransson P. Efficacy of mistletoe extract as a complement to standard treatment in advanced pancreatic cancer: study protocol for a multicentre, parallel group, double-blind, randomised, placebo-controlled clinical trial (MISTRAL). Trials 21, 783 (2020). https://doi.org/10.1186/s13063-020-04581-y
Wode K, Schneider T, Lundberg I and Kienle G S. Mistletoe treatment in cancer-related fatigue: a case report. Cases J, 2009;2:77. DOI: 10.1186/1757-1626-2-77.
Wong C K, Zhang J, Ip W K and Lam C W. Intracellular signal transduction in eosinophils and its clinical significance. Immunopharmacol Immunotoxicol, 2002;24:165-186. DOI: 10.1081/IPH-120003748.
Xie W, Adolf J, Melzig MF. Identification of Viscum album L. miRNAs and prediction of their medicinal values. PloS one 2017;12(11):20 pp., article ID e0187776. DOI: 10.1371/journal. pone. 0187776.
Yang, P, Jiang, Y, Pan, Y, et al. Mistletoe extract fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression. Sci Rep. 2019;9(1):6428. doi:10.1038/s41598-019-41444-2
Google Scholar | Crossref | Medline
Zänker KS, Matthes H, Bock PR, Hanisch J (2012) A Specific Mistletoe Preparation (Iscador-Qu®) in Colorectal Cancer (CRC) Patients: More than Just Supportive Care? J Cancer Sci Ther 4: 264-270. doi: 10.4172/1948-5956.1000153
Zerm R, Müller-Glinz A, Pranga D, Reif M, Bartsch C, Heckmann C, Gutenbrunner C, Kröz M. Influence of multimodal treatment on rest/activity and autonomic regulation in breast cancer patients with cancer related fatigue - results of a tri-center trial with a comprehensive cohort design, Complement Med Res. (2022). https://doi.org/10.1159/000527354.
Ziegler R and Grossarth-Maticek R. Individual Patient Data Meta-analysis of Survival and Psychosomatic Self-regulation from Published Prospective Controlled Cohort Studies for Long-term Therapy of Breast Cancer Patients with a Mistletoe Preparation (Iscador). Evid Based Complement Alternat Med, 2010;7:157-166. DOI: 10.1093/ecam/nen025.
Zuzak TJ, Wasmuth A, Bernitzki S, Schwermer M, Längler A. Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series. Complement Ther Med. 2018 Oct;40:198-202. Epub 2018 Jan 11. DOI: 10.1016/j.ctim.2018.01.002.